223 related articles for article (PubMed ID: 16322479)
1. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy.
Hill A; Ridley SH; Esser D; Oldroyd RG; Cullen MJ; Kareclas P; Gallagher S; Smith GP; Richards SJ; White J; Smith RA; Hillmen P
Blood; 2006 Mar; 107(5):2131-7. PubMed ID: 16322479
[TBL] [Abstract][Full Text] [Related]
2. Correction of the PNH defect by GPI-anchored protein transfer.
Sloand EM; Maciejewski JP; Dunn D; Moss J; Brewer B; Kirby M; Young NS
Blood; 1998 Dec; 92(11):4439-45. PubMed ID: 9834251
[TBL] [Abstract][Full Text] [Related]
3. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
[TBL] [Abstract][Full Text] [Related]
5. Paroxysmal nocturnal hemoglobinuria (PNH) and primary p.Cys89Tyr mutation in CD59: Differences and similarities.
Mevorach D
Mol Immunol; 2015 Sep; 67(1):51-5. PubMed ID: 25818314
[TBL] [Abstract][Full Text] [Related]
6. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
[TBL] [Abstract][Full Text] [Related]
7. Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis.
Babiker AA; Ronquist G; Nilsson UR; Nilsson B
Am J Reprod Immunol; 2002 Mar; 47(3):183-92. PubMed ID: 12069204
[TBL] [Abstract][Full Text] [Related]
8. Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement.
Rother RP; Rollins SA; Mennone J; Chodera A; Fidel SA; Bessler M; Hillmen P; Squinto SP
Blood; 1994 Oct; 84(8):2604-11. PubMed ID: 7522635
[TBL] [Abstract][Full Text] [Related]
9. [Protection of PNH red blood cells from lysis by transferring GPI-anchored protein vesicles of normal human RBCs in vitro].
Yang Y; Xu C; Pan H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Aug; 21(4):278-81. PubMed ID: 12567450
[TBL] [Abstract][Full Text] [Related]
10. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.
Risitano AM; Ricklin D; Huang Y; Reis ES; Chen H; Ricci P; Lin Z; Pascariello C; Raia M; Sica M; Del Vecchio L; Pane F; Lupu F; Notaro R; Resuello RR; DeAngelis RA; Lambris JD
Blood; 2014 Mar; 123(13):2094-101. PubMed ID: 24497537
[TBL] [Abstract][Full Text] [Related]
11. Paroxysmal nocturnal hemoglobinuria and the age of therapeutic complement inhibition.
Varela JC; Brodsky RA
Expert Rev Clin Immunol; 2013 Nov; 9(11):1113-24. PubMed ID: 24168416
[TBL] [Abstract][Full Text] [Related]
12. Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.
Lee M; Narayanan S; McGeer EG; McGeer PL
PLoS One; 2014; 9(1):e87316. PubMed ID: 24489894
[TBL] [Abstract][Full Text] [Related]
13. Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells.
Yuan FF; Bryant JA; Fletcher A
Immunol Cell Biol; 1995 Feb; 73(1):66-72. PubMed ID: 7539403
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.
Luzzatto L; Gianfaldoni G
Int J Hematol; 2006 Aug; 84(2):104-12. PubMed ID: 16926130
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
[TBL] [Abstract][Full Text] [Related]
16. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
17. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
Risitano AM
Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
[TBL] [Abstract][Full Text] [Related]
18. New insights into paroxysmal nocturnal hemoglobinuria.
Brodsky RA
Hematology Am Soc Hematol Educ Program; 2006; ():24-8, 516. PubMed ID: 17124035
[TBL] [Abstract][Full Text] [Related]
19. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes.
Ferreira VP; Pangburn MK
Blood; 2007 Sep; 110(6):2190-2. PubMed ID: 17554058
[TBL] [Abstract][Full Text] [Related]
20. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
